Neoleukin Therapeutics Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
Hello, everyone, and welcome. I am Charles Zhu, one of the senior biotech analysts here at Guggenheim Securities. Our next fireside chat will be with Neoleukin, a next-gen engineered cytokine platform. Joining us here today is Jonathan Drachman, CEO.
Jonathan, thank you so very much for your time today. We always appreciate your participation in our events. Before we get started with Q&A, could you perhaps kick us off with a high-level, two- to three-minute intro and overview of your Company, pipeline, and platform?
Thanks, Charles. It's a pleasure to be here. Thanks for the invitation. Thanks to Guggenheim. So Neoleukin Therapeutics was founded as a de novo protein design company. And it's based on the technology that originated from the University of Washington in the Institute for Protein Design, demonstrating that you could use computational algorithms to design a completely de novo protein to have a specific structure and function.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
